3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
2
Thyroid Nodule
1
Prostatic Neoplasms
1
Multiple Pulmonary Nodules
1
Hyperaldosteronism
1
Carcinoma, Renal Cell
1
Bone Cancer Metastatic
1
Barrett Esophagus
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
ACTH Syndrome, Ectopic
1
Interventions
Magnetic Resonance Spectroscopy
49
enzalutamide
46
apalutamide
36
Specimen Handling
34
Androgen Antagonists
30
Abiraterone Acetate
29
Radiosurgery
27
Prednisone
26
darolutamide
25
Docetaxel
23
Pluvicto
22
abiraterone
20
Radiotherapy
19
Biopsy
17
Leuprolide
15
relugolix
11
gallium 68 PSMA-11
11
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
Surveys and Questionnaires
11
Radiation
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
Standard of Care
10
Nivolumab
10
cabazitaxel
9
X-Rays
9
Triptorelin Pamoate
9
bicalutamide
8
Carboplatin
8
pembrolizumab
7
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Radiofrequency Ablation
×
90 days
×
Clear all
NCT07237399
2026-05-13
TA-P-OLIM
University Hospital, Ghent
Withdrawn